Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qutenza Versus Pregabalin in Peripheral Neuropathic Pain
NCT01713426Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2012
- Primary completion
- Sep 2013
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 22
01
Overview
Phase 4, randomised, open-label trial of capsaicin 8% patch in Peripheral neuropathic pain, postherpetic neuralgia (PHN), peripheral nerve injury (PNI) and 1 more (2 arms), sponsored by Astellas Pharma. Primary endpoint: Proportion of subjects achieving at least 30% decrease in Numeric Pain Rating Scale at 8 weeks. Started Jul 2012; status: completed.
02
Drugs
capsaicin 8% patch
03
Conditions
Peripheral neuropathic painpostherpetic neuralgia (PHN)peripheral nerve injury (PNI)Non-diabetic Peripheral Polyneuropathy
Beyond the preview
Go deeper on NCT01713426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01713426.